Ann: Quarterly Activities Report, page-8

In my view, there's way too much elite executive talent (mostly with skin in the game) for anything less than something really big to happen here.

It's an all star line up in a micro cap with a healthy cash position & no cheap options overhang. Neither has there been any cheap suits conducting pump & dumps.

More specifically, the company has in key roles the 3 biggest industry names in 3 very lucrative continents in Dr Sud, Vijay Sappani (North America) & Dr Saich (UK).

Not to mention the CEO Matthew Golden is ex big Pharma (Pfizer) & Darryl Davies, co-founder of Cannvalate, is hardly a slouch.

There is no weak link in this chain & the register is also rock solid, especially now the German legacy holders are just about out.

There is barely any retail in this at all outside the few of us who post here.

The top 20 hold more than 70%, most of whom would have an average not too far south of here.

Indeed, the 2 biggest holders have been adding at 10 cents and over.

It's a matter of when not if.

Gltah